Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer / Rimawi, M. F.; de Angelis, C.; Contreras, A.; Pareja, F.; Geyer, F. C.; Burke, K. A.; Herrera, S.; Wang, T.; Mayer, I. A.; Forero, A.; Nanda, R.; Goetz, M. P.; Chang, J. C.; Krop, I. E.; Wolff, A. C.; Pavlick, A. C.; Fuqua, S. A. W.; Gutierrez, C.; Hilsenbeck, S. G.; Li, M. M.; Weigelt, B.; Reis-Filho, J. S.; Osborne, C. K.; Schiff, R.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 167:3(2018), pp. 731-740. [10.1007/s10549-017-4533-9]
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
de Angelis C.Secondo
;
2018
Abstract
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
